GRI Bio, Inc., a development stage biotech company, develops Natural Killer T (NKT) cell-based therapies for liver disease and autoimmunity. Its program includes GRI-0621, an inhibitor of type 1 NKT cells that is developed as an oral therapeutic for liver disease. GRI Bio, Inc. was formerly know as Glycoregimmune, Inc. GRI Bio, Inc. was incorporated in 2009 and is based in LA Jolla, California.āāā⦠read more
Healthcare
Biotechnology
2 years
USD
Exclusive to Premium users
$2.01
Price-2.43%
-$0.05
$5.056m
Small
0x
Premium
Premium
-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin$0.00
-
1y CAGR-
3y CAGR-
5y CAGR-$10.008m
-
1y CAGR-
3y CAGR-
5y CAGR-$25.87
-
1y CAGR-
3y CAGR-
5y CAGR$3.322m
$5.675m
Assets$2.353m
Liabilities$96k
Debt1.7%
-
Debt to EBITDA-$9.169m
-
1y CAGR-
3y CAGR-
5y CAGR